| P50 | author | Ken Fujise | Q93046258 |
| P2093 | author name string | Decha Pinkaew | |
| | Perumal Thiagarajan | |
| | Patuma Sinthujaroen | |
| | Preedakorn Chunhacha | |
| | Hasseri Halim | |
| P2860 | cites work | Differential expression of three T lymphocyte-activating CXC chemokines by human atheroma-associated cells | Q24563090 |
| | Transcript assembly and quantification by RNA-Seq reveals unannotated transcripts and isoform switching during cell differentiation | Q24627354 |
| | Differential gene and transcript expression analysis of RNA-seq experiments with TopHat and Cufflinks | Q24633890 |
| | Lamin proteolysis facilitates nuclear events during apoptosis | Q24681695 |
| | Cell death and diseases related to oxidative stress: 4-hydroxynonenal (HNE) in the balance | Q27693875 |
| | Mice lacking serum paraoxonase are susceptible to organophosphate toxicity and atherosclerosis | Q28592044 |
| | Ticagrelor versus clopidogrel in patients with acute coronary syndromes | Q29619002 |
| | GARP2 accelerates retinal degeneration in rod cGMP-gated cation channel β-subunit knockout mice. | Q30398618 |
| | ADAMTS13 reduces vascular inflammation and the development of early atherosclerosis in mice | Q30511960 |
| | Atherosclerotic plaque rupture--pathologic basis of plaque stability and instability | Q33643432 |
| | Toll-like receptor 7 deficiency protects apolipoprotein E-deficient mice from diet-induced atherosclerosis | Q33678336 |
| | Pharmacokinetics, pharmacodynamics, safety and tolerability of multiple ascending doses of ticagrelor in healthy volunteers | Q34019342 |
| | Absorption, distribution, metabolism, and excretion of ticagrelor in healthy subjects | Q34120974 |
| | Tumor necrosis factor-alpha in human arterial wall with atherosclerosis | Q34700760 |
| | Ticagrelor: pharmacokinetics, pharmacodynamics, clinical efficacy, and safety | Q34805121 |
| | Physical and functional antagonism between tumor suppressor protein p53 and fortilin, an anti-apoptotic protein | Q35213271 |
| | Early growth response 1 (Egr1) regulates cholesterol biosynthetic gene expression | Q35313420 |
| | Atherosclerotic Plaque Stability Is Affected by the Chemokine CXCL10 in Both Mice and Humans | Q35582482 |
| | Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents | Q35783487 |
| | A Potential Mechanism of High-Dose Ticagrelor in Modulating Platelet Activity and Atherosclerosis Mediated by Thymic Stromal Lymphopoietin Receptor | Q35827283 |
| | Morelloflavone, a biflavonoid inhibitor of migration-related kinases, ameliorates atherosclerosis in mice | Q35921239 |
| | Clopidogrel significantly lowers the development of atherosclerosis in ApoE-deficient mice in vivo. | Q53471537 |
| | Ticagrelor | Q61668621 |
| | A new platelet function test | Q67295105 |
| | Identification of active tissue factor in human coronary atheroma | Q71571184 |
| | Flow cytometry analysis of intracellular VASP phosphorylation for the assessment of activating and inhibitory signal transduction pathways in human platelets--definition and detection of ticlopidine/clopidogrel effects | Q73013573 |
| | Increased immunolocalization of paraoxonase, clusterin, and apolipoprotein A-I in the human artery wall with the progression of atherosclerosis | Q73596679 |
| | Transforming growth factor-beta mediates balance between inflammation and fibrosis during plaque progression | Q74309008 |
| | Pathology of the vulnerable plaque | Q83187650 |
| | Chemokine CXCL10 promotes atherogenesis by modulating the local balance of effector and regulatory T cells | Q83305041 |
| | Macrophage inflammatory protein-1β and fibrinogen are synergistic predictive markers of prognosis of intermediate coronary artery lesions | Q83540593 |
| | Pharmacokinetics, Pharmacodynamics, and Safety of Ticagrelor in Volunteers With Mild Hepatic Impairment | Q85167435 |
| | Protein detection by Simple Western™ analysis | Q85312527 |
| | Light transmission aggregometry | Q86519312 |
| | Adenosine and Ticagrelor Plasma Levels in Patients With and Without Ticagrelor-Related Dyspnea | Q88792905 |
| | Assessment of a flow cytometry technique for studying signaling pathways in platelets: Monitoring of VASP phosphorylation in clinical samples | Q91373933 |
| | Failure to Recognize Novelty after Extended Methamphetamine Self-Administration Results from Loss of Long-Term Depression in the Perirhinal Cortex | Q36059937 |
| | Ticagrelor versus Clopidogrel in Symptomatic Peripheral Artery Disease | Q36221940 |
| | Platelet P2Y12 Inhibitors Reduce Systemic Inflammation and Its Prothrombotic Effects in an Experimental Human Model. | Q36330189 |
| | Fortilin potentiates the peroxidase activity of Peroxiredoxin-1 and protects against alcohol-induced liver damage in mice. | Q36423249 |
| | Jnk1 Deficiency in Hematopoietic Cells Suppresses Macrophage Apoptosis and Increases Atherosclerosis in Low-Density Lipoprotein Receptor Null Mice. | Q36940644 |
| | Absolute bioavailability and regional absorption of ticagrelor in healthy volunteers | Q37077147 |
| | Ticagrelor promotes atherosclerotic plaque stability in a mouse model of advanced atherosclerosis | Q37225795 |
| | Inhibition of platelet activation by clopidogrel prevents hypertension-induced cardiac inflammation and fibrosis | Q37314369 |
| | Fortilin reduces apoptosis in macrophages and promotes atherosclerosis | Q37342158 |
| | Rewiring of jasmonate and phytochrome B signalling uncouples plant growth-defense tradeoffs. | Q37502046 |
| | Standardizing a simpler, more sensitive and accurate tail bleeding assay in mice | Q37527691 |
| | P2Y(12) inhibitors: differences in properties and mechanisms of action and potential consequences for clinical use. | Q37562606 |
| | Platelet P2Y12 receptor inhibition by thienopyridines: status and future | Q37579228 |
| | Targeting paraoxonase-1 in atherosclerosis | Q38097853 |
| | Adenosine-mediated effects of ticagrelor: evidence and potential clinical relevance | Q38207389 |
| | Novel antiplatelet agents in acute coronary syndrome | Q38257119 |
| | Effects of P2Y12 receptor antagonists beyond platelet inhibition--comparison of ticagrelor with thienopyridines | Q38694069 |
| | Long-Term Use of Ticagrelor in Patients with Coronary Artery Disease. | Q39093174 |
| | Hepatocellular toxicity of clopidogrel: mechanisms and risk factors | Q39139225 |
| | Long-term use of ticagrelor in patients with prior myocardial infarction | Q40263764 |
| | Interleukin-6 exacerbates early atherosclerosis in mice | Q40793841 |
| | Combined serum paraoxonase knockout/apolipoprotein E knockout mice exhibit increased lipoprotein oxidation and atherosclerosis | Q41728164 |
| | Tumor necrosis factor enhances expression of tissue factor mRNA in endothelial cells. | Q42498203 |
| | Mortality benefit in PLATO cannot be explained by antiplatelet properties of ticagrelor | Q42760647 |
| | Inhibitory effects of ticagrelor compared with clopidogrel on platelet function in patients with acute coronary syndromes: the PLATO (PLATelet inhibition and patient Outcomes) PLATELET substudy | Q42910350 |
| | Ticagrelor increases adenosine plasma concentration in patients with an acute coronary syndrome. | Q43873602 |
| | Low paraoxonase activity predicts coronary events in the Caerphilly Prospective Study | Q44447076 |
| | Hepatic gene expression profiling reveals perturbed calcium signaling in a mouse model lacking both LDL receptor and Apobec1 genes | Q44512715 |
| | Inhibition of tumor necrosis factor-alpha reduces atherosclerosis in apolipoprotein E knockout mice | Q45042448 |
| | Apolipoprotein E modulates clearance of apoptotic bodies in vitro and in vivo, resulting in a systemic proinflammatory state in apolipoprotein E-deficient mice | Q45140669 |
| | Immunohistochemical analysis of paraoxonases-1 and 3 in human atheromatous plaques | Q45343506 |
| | Pharmacokinetics, pharmacodynamics, and safety of ticagrelor in volunteers with severe renal impairment | Q45365025 |
| | Pro-inflammatory role of platelets in hypertension-mediated end-organ damage : Editorial to: "Inhibition of Platelet activation by clopidogrel prevents hypertension-induced cardiac inflammation and fibrosis" by L.-X. Jia et al. | Q45729733 |
| | Detection and localization of tumor necrosis factor in human atheroma | Q46152807 |
| | The mechanism and risk factors of clopidogrel-induced liver injury | Q46625831 |
| | Characterization of the adenosine pharmacology of ticagrelor reveals therapeutically relevant inhibition of equilibrative nucleoside transporter 1. | Q46707933 |
| | Progression of atherosclerosis in ApoE-deficient mice that express distinct molecular forms of TNF-alpha | Q46773827 |
| | A mouse model of human familial hypercholesterolemia: markedly elevated low density lipoprotein cholesterol levels and severe atherosclerosis on a low-fat chow diet. | Q46778536 |
| | Prasugrel versus clopidogrel in patients with acute coronary syndromes | Q46915044 |
| | Interleukin-6 is an independent predictor of progressive atherosclerosis in the carotid artery: The Tromsø Study | Q49916343 |
| | Ticagrelor, but not clopidogrel, reduces arterial thrombosis via endothelial tissue factor suppression. | Q50986493 |
| | Deficiency of tissue factor pathway inhibitor promotes atherosclerosis and thrombosis in mice. | Q52543322 |
| P275 | copyright license | Creative Commons CC0 License | Q6938433 |
| P6216 | copyright status | copyrighted, dedicated to the public domain by copyright holder | Q88088423 |
| P433 | issue | 6 | |
| P921 | main subject | clopidogrel | Q410237 |
| P304 | page(s) | e0218934 | |
| P577 | publication date | 2019-06-26 | |
| P1433 | published in | PLOS One | Q564954 |
| P1476 | title | Ticagrelor induces paraoxonase-1 (PON1) and better protects hypercholesterolemic mice against atherosclerosis compared to clopidogrel | |
| P478 | volume | 14 | |